PRI's Focus on Health Care

View this email in your browser ([link removed])
[link removed]
[link removed]

The Flawed Third-Party Payer System Drives the Drug Affordability Problem

Pacific Research Institute | Wayne Winegarden
March 1, 2022

The flaws of the current insurance system undermine the quality of the U.S. drug market and fail to provide patients with the essential service of mitigating the financial risks associated with requiring high cost medicines. The result is the high-profile drug affordability problem. Improving drug affordability and promoting drug innovation, which is a core measure of improving quality in the drug market, requires improvements to how the insurance industry provides drug insurance coverage.

Read more. . . ([link removed])
[link removed]

Don't Dam the Telehealth Flood

Forbes | Sally C. Pipes
February 28, 2022

To say that Americans are anxiously awaiting the end of the COVID-19 pandemic would be an understatement. But for patients who have enjoyed the ease of attending doctor’s appointments virtually, a return to the way things were pre-pandemic might be bittersweet.

That’s because onerous restrictions on telemedicine, which lawmakers relaxed when COVID-19 hit, could be reinstated once officials declare the public health emergency over.
Read more. . . ([link removed])
[link removed]

What science says about the future of COVID-19

American Council on Science and Health | Henry Miller and Melissa Hart
March 1, 2022

The best strategies are those that prevent becoming infected in the first place, so for now, the most prudent course is still to get vaccinated, boosted, and take other reasonable precautions to “flatten the curve” of infections. The fewer infections, the less viral replication, the fewer mutants, and the less likelihood of new, worse variants.

Read more. . . ([link removed])
[link removed]

Violating Manufacturer's Property Rights Does Not Promote Healthy Competition

Forbes | Wayne Winegarden
February 28, 2022

Under the pretense of promoting competition, states as diverse as Texas ([link removed]) and California ([link removed]) , Arkansas ([link removed]) and Hawaii ([link removed]) have all considered bills that would violate medical device companies’ intellectual property rights. While many have been defeated, some legislators seem intent on advancing one businesses interest over another, which undermines competitive efficiency and, in the case of medical devices, creates risks to patient care.

Read more. . . ([link removed])

============================================================
** ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])
Copyright © 2022 *Pacific Research Institute*, All rights reserved.
You are receiving this email because you opted in via our website.

Our mailing address is:
P.O. Box 60485 | Pasadena, CA 91116

Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.